|
Eli Lilly's next-generation obesity drug retatrutide clears first late-stage diabetes trial CNBCLilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli LillyLilly's Experimental Diabetes Shot Yields Record Weight Loss in Study Bloomberg.comLilly's triple-G bet lowers blood sugar, prompts 1
|
|
